HOME >> BIOLOGY >> NEWS
Skin rash actually signifies better outcomes for pancreatic and lung cancer patients

The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drugs developer, OSI Pharmaceuticals, Inc. This is not the first time that rash has been associated with a survival advantage with EGFR inhibitors a class of drugs which includes erlotinib, cetuximab, panitumumab and others designed to block overproduction of the epidermal growth factor receptor but it is the most detailed analysis to date.

The study, published in the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, reports that for patients taking Tarceva who developed a moderate to severe rash, survival without progression of disease was 245 percent longer than in patients who had a mild rash or none at all. In fact, in the majority of cases, the more severe the rash, the longer a patients cancer was held in check, researchers found.

This rash, which often looks like acne, can be unpleasant enough for some people to consider discontinuing treatment, but it is important for physicians and patients to understand that this a positive event because it means there is likely to be a better clinical outcome, said the lead author, Bret Wacker, MS Director of Biostatistics at OSI Pharmaceuticals, Inc. Further studies are needed to both identify patients most likely to develop rash and to determine if dose escalation to induce rash can improve efficacy.

Although few patients dropped out of the large Phase III clinical trials testing Tarceva in advanced non-small cell lung cancer and pancreatic cancer due to the rash, Wacker said he fears those who are taking Tarceva outside of a clinical trial may be likely to stop treatment.

Some patients are stopping treatment because of the rash, yet those are the ones who are most likely to benefit, Wacker said. This is a critical problem and rather than permanently discontinue tr
'"/>

Contact: Greg Lester
lester@aacr.org
267-646-0554
American Association for Cancer Research
3-Jul-2007


Page: 1 2 3

Related biology news :

1. Throwing motion in young baseball players may actually protect shoulder
2. Mysterious neural noise actually primes brain for peak performance
3. Do green markets actually lead to improvements in environmental quality?
4. Innovative tagging technique may help researchers better protect fish stocks
5. Gene predicts better outcome as cortex normalizes in teens with ADHD
6. Handicapping tuberculosis may be the way to a better vaccine
7. Military to study better pain relief in battle zones
8. Wider buffers are better
9. More fish oil, less vegetable oil, better for your health
10. Losing weight after pregnancy -- diet and exercise better than diet alone
11. Decoding mushrooms secrets could combat carbon, find better biofuels and safer soils

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2018)... ... September 21, 2018 , ... VTE can ... untreated, can lead to significant morbidity and mortality. VTE affects between 300-600,000 Americans ... autopsy. Further, PE is the leading cause of preventable hospital death and maternal ...
(Date:9/12/2018)... ... September 11, 2018 , ... Tennant ... introduce the new ChemXP™ line of high performance secondary containment coatings, designed to ... to provide Tennant Coatings’ elite certified installers with the needed solutions to protect ...
(Date:9/7/2018)... ... September 06, 2018 , ... Sensors Midwest ... show Sensors Expo & Conference , announces their partnership with Fraunhofer USA ... an IoT Enabled Industrial IoT Certification Program. Taking place on October 17, 2018 ...
Breaking Biology News(10 mins):
(Date:9/13/2018)... ... September 13, 2018 , ... Asymmetrex’s director, James L. ... have gotten in medicine, if we didn’t have the means to measure the number ... His answer, “Nowhere! And that is what’s holding up progress in stem cell ...
(Date:9/12/2018)... ... 11, 2018 , ... Sterlitech Corporation, a global leader in ... from Fluid Technology Solutions (FTS H2O) to their offering of filtration products. ... triacetate (CTA) material. The highly hydrophilic nature of the CTA FO membranes favors ...
(Date:9/7/2018)... ... September 06, 2018 , ... ... September 25th-28th is a meeting of “The industry’s preeminent event on novel drug ... discovery scientists powerful tools to study these emerging targets in a quest to ...
(Date:9/7/2018)... , ... September 06, 2018 , ... Akadeum Life Sciences ... spent his career as an executive and leader of numerous biotech companies. , ... therapy and biologics company acquired by Thompson Street Capital in St. Louis, MO. ...
Breaking Biology Technology:
Cached News: